BVS

Bioventus Inc. ( BVS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants David Crawford - Vice President of Investor Relations & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - Senior VP & CFO Conference Call Participants Caitlin Cronin - Canaccord Genuity Corp., Research Division Lawrence Solow - CJS Securities, Inc. Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Presentation Operator Good afternoon, and welcome to the Bioventus Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

DURHAM, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 26, 2026.

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2026 after the market closes on Monday, November 2, 2026. The Company's management will host a conference call at 4:30 p.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. Execution focus is on demonstrating sustained cash flows, successful new product adoption, and repeat physician usage, not just early launch revenue.

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.

Bioventus (BVS) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.21 per share a year ago.